Zacks Investment Research
INSM Stock Slides on CFO Exit, Reiterates '26 Sales ViewInsmed's stock fell nearly 7% following the announcement that CFO Sara Bonstein will step down effective October 30 after nearly seven years in the role. Despite the leadership transition, the company reaffirmed its 2026 revenue guidance, expecting Brinsupri revenues of $1.25-$1.40 billion and Arikayce sales of $450-$470 million. The decline reflects investor uncertainty about the unexpected departure of a key executive during a critical growth phase.